Company History |
NK4 is a molecule, discovered by Prof. Toshikazu Nakamura and Associate Prof. Kunio Matsumoto, that inhibits tumor angiogenesis and cancer metastasis. It is an innovative technology that holds malignant tumors at the stage of freeze or dormancy.
Kringle Pharma, Inc. was established as a pharmaceutical biotechnology venture company originating from Osaka University in December 2001 with the goal of early development of new cancer therapies utilizing NK4.
Prof. Nakamura and Associate Prof. Matsumoto, the reseaerchers who discovered NK4, became deeply engaged in the establishment of Kringle Pharma, Inc. Associate Prof. Matsumoto is the Chief Scientific Officer for the company, a position he has held since October 2002.
Mr. Kunio Iwatani, President and CEO of Kringle Pharma, Inc., was previously engaged in the expansion of business for the International Division of Takeda Chemical Ind. Ltd. for nineteen years. After holding the positions of President and CEO of Hokuriku Seiyaku Co. Ltd. and Director of Abbott Japan Co. Ltd. successively, he has filled the present position as President and CEO since March 1, 2003.
|
|
